InteKrin Therapeutics Announces INT131 Phase 2a Results At The 2009 American Diabetes Association Annual Meeting
InteKrin Therapeutics Inc presented Phase 2a clinical study results at the American Diabetes Association annual meeting in New Orleans demonstrating that once a day oral treatment with INT131 provides anti-diabetic efficacy consistent with maximal dose thiazolidinedione (TZD) therapy but with less hematocrit reduction and weight gain.
More: continued here
Filed under: Conferences on June 21st, 2009
You must be logged in to post a comment.